1Ahmedin Jemal, DVM, Ph D, et al. Cancer Statistics, 2010. CA cancer J Clin ,2010,60:277 - 300.
2Hessels D, Klein - Gunnewiek JM, Van Oort I, et al. DD3 ( PCA3 ) - based molecular urine analysis for the diagnosis of prostate canc- er. Eur Urol,2003,44(1 ) :8 - 16.
3Mistry K, Cable G. Meta -analysis of prostate specific antigen and digital rectal examination as screening test s for prostate carcinoma. J Am Board Faro Pract,2003,16(2) :95 -101.
5Thomason I M,pauler D K,Goodmen P J,et al. Prevalence of pros- tate cancer among men with a Prostate Specific Antigen lever < or = 4.0ng/ml. NEJM,20( ,350(22) : 2239 -2246.
6Fink KG, Hutarew G, Pytel A,et al. One 10 -core prostate biopsy is superior to two sets of sextant prostate biopsies. BJU Int,2003, 92:385 - 388.
7Djavan B, Zlotta A, Remzi M,et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 men. J Urol,2000,163:1144 - 1149.
8Bussemakers M J, van Bokhoven A, Verhaegh GW, et al. DD3:A new prostate - specific gene. highly overexpressed in prostate canc- er. Cancer Res. J Cancer Res, 1999,59:5975 -5979.
9Schaiken J A, Hessels D ,Verhaegh G. New target s for therapy in prostate cancer: differential display code 3 ( DD3 PCA3 ) , a highly prostate cancer- specific gene. Urology,2003,62 (Suppl 5A) :34 -43.
10Gandini O, Luci L, Stigliano A, et al. Is DD3 a new prostate - spe- cific gene. Anticancer Res ,2003 ,23 ( 1 A ) : 305 - 308.
6Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer, Cancer Res, 1999, 59(23): 5975-5979.
7Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice, Rev Urol, 2008, 10(3): 175-181.
8Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer, Nat Rev Urol, 2009, 6(5): 255-261.
9Culig Z, Steiner H, Barstsch G, et al. Mechanisms of endocrine therapy-responsive and unresponsive prostate tumours, Endocr Relat Cancer, 2005, 12(2): 229-244.
10Steiner MS, Gingrich JR. Gene therapy for prostate cancer:where are we now, J Urol, 2000, 164(4): 1121-1136.
